Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kala Pharmaceuticals Q2 EPS $(4.36) Up From $(18.92) YoY; $59.2M In Cash, Cash Equivalents And Short-Term Expected To Fund Operations Into 2Q 2025

Author: Benzinga Newsdesk | August 04, 2023 08:03am
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(4.36) per share. This is a 76.96 percent increase over losses of $(18.92) per share from the same period last year.

Posted In: KALA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist